A randomized phase II trial of best supportive care with or without hyperthermia and vitamin C for heavily pretreated, advanced, refractory non-small-cell lung cancer

[Display omitted] Our previous study indicated that intravenous vitamin C (IVC) treatment concurrent with modulated electrohyperthermia (mEHT) was safe and improved the quality of life (QoL) of non-small-cell lung cancer (NSCLC) patients. The aim of this trial was to further verify the efficacy of t...

Full description

Saved in:
Bibliographic Details
Published in:Journal of advanced research 2020-07, Vol.24, p.175-182
Main Authors: Ou, Junwen, Zhu, Xinyu, Chen, Pengfei, Du, Yanping, Lu, Yimin, Peng, Xiufan, Bao, Shuang, Wang, Junhua, Zhang, Xinting, Zhang, Tao, Pang, Clifford L.K.
Format: Article
Language:English
Subjects:
Modulated electrohyperthermia
Non-small-cell lung cancer
Overall survival
Quality of life
Remission rate
Vitamin C
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:[Display omitted] Our previous study indicated that intravenous vitamin C (IVC) treatment concurrent with modulated electrohyperthermia (mEHT) was safe and improved the quality of life (QoL) of non-small-cell lung cancer (NSCLC) patients. The aim of this trial was to further verify the efficacy of the above combination therapy in previously treated patients with refractory advanced (stage IIIb or IV) NSCLC. A total of 97 patients were randomized to receive IVC and mEHT plus best supportive care (BSC) (n = 49 in the active arm, receiving 1 g/kg * d IVC concurrently with mEHT, three times a week for 25 treatments in total) or BSC alone (n = 48 in the control arm). After a median follow-up of 24 months, progression-free survival (PFS) and overall survival (OS) were significantly prolonged by combination therapy compared to BSC alone (PFS: 3 months vs 1.85 months, P 
ISSN:2090-1232
2090-1224
DOI:10.1016/j.jare.2020.03.004